Literature DB >> 14561524

Tissue microarray study for classification of breast tumors.

Dao-Hai Zhang1, Manuel Salto-Tellez, Lily-Lily Chiu, Liang Shen, Evelyn Siew-Chuan Koay.   

Abstract

Clinical and pathological heterogeneity of breast cancer hinders selection of appropriate treatment for individual cases. Molecular profiling at gene or protein levels may elucidate the biological variance of tumors and provide a new classification system that correlates better with biological, clinical and prognostic parameters. We studied the immunohistochemical profile of a panel of seven important biomarkers using tumor tissue arrays. The tumor samples were then classified with a monothetic (binary variables) clustering algorithm. Two distinct groups of tumors are characterized by the estrogen receptor (ER) status and tumor grade (p = 0.0026). Four biomarkers, c-erbB2, Cox-2, p53 and VEGF, were significantly overexpressed in tumors with the ER-negative (ER-) phenotype. Eight subsets of tumors were further identified according to the expression status of VEGF, c-erbB2 and p53. The malignant potential of the ER-/VEGF+ subgroup was associated with the strong correlations of Cox-2 and c-erbB2 with VEGF. Our results indicate that this molecular classification system, based on the statistical analysis of immunohistochemical profiling, is a useful approach for tumor grouping. Some of these subgroups have a relative genetic homogeneity that may allow further study of specific genetically-controlled metabolic pathways. This approach may hold great promise in rationalizing the application of different therapeutic strategies for different subgroups of breast tumors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14561524     DOI: 10.1016/j.lfs.2003.05.006

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  9 in total

1.  RUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor α.

Authors:  B Huang; Z Qu; C W Ong; Y-H N Tsang; G Xiao; D Shapiro; M Salto-Tellez; K Ito; Y Ito; L-F Chen
Journal:  Oncogene       Date:  2011-06-27       Impact factor: 9.867

2.  Activating mechanism of transcriptor NF-kappaB regulated by hepatitis B virus X protein in hepatocellular carcinoma.

Authors:  Tao Wang; Yi Wang; Meng-Chao Wu; Xin-Yuan Guan; Zheng-Feng Yin
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

3.  Lipid-rich histology in a basal-type immuno-profile breast carcinoma: a clinicopathological histochemical and immunohistochemical analysis of a case.

Authors:  Serena Russo; Diana Coppola; Paola Vinaccia; Antonella Siciliano; Francesca Baldassarre; Giovanni Battista; Giuseppe Pisani; Joseph Sepe; Francesco M Maiello
Journal:  Rare Tumors       Date:  2009-12-28

4.  Clinical proteomics of breast cancer.

Authors:  Y Baskın; T Yiğitbaşı
Journal:  Curr Genomics       Date:  2010-11       Impact factor: 2.236

5.  The clinical applications of a systems approach.

Authors:  Andrew C Ahn; Muneesh Tewari; Chi-Sang Poon; Russell S Phillips
Journal:  PLoS Med       Date:  2006-05-23       Impact factor: 11.069

6.  COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer.

Authors:  A V Timoshenko; C Chakraborty; G F Wagner; P K Lala
Journal:  Br J Cancer       Date:  2006-04-24       Impact factor: 7.640

7.  Tissue microarrays characterise the clinical significance of a VEGF-A protein expression signature in gastrointestinal stromal tumours.

Authors:  M Salto-Tellez; M E Nga; H C Han; A S-C Wong; C K Lee; D Anuar; S S Ng; M Ho; A Wee; Y H Chan; R Soong
Journal:  Br J Cancer       Date:  2007-02-13       Impact factor: 7.640

8.  Immunoprofile from tissue microarrays to stratify familial breast cancer patients.

Authors:  Laura Schirosi; Simona De Summa; Stefania Tommasi; Angelo Paradiso; Domenico Sambiasi; Ondina Popescu; Giovanni Simone; Anita Mangia
Journal:  Oncotarget       Date:  2015-09-29

9.  Prolyl isomerase Pin1 downregulates tumor suppressor RUNX3 in breast cancer.

Authors:  Y-H Nicole Tsang; X-W Wu; J-S Lim; C Wee Ong; M Salto-Tellez; K Ito; Y Ito; L-F Chen
Journal:  Oncogene       Date:  2012-05-14       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.